Madrigal Pharmaceuticals shares rose after the biopharmaceutical company received a U.S. patent for its Rezdiffra treatment. Shares were up 11% at $345.24 Wednesday. The stock has been up 12.8% this ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) saw its stock climb 6.1% following the announcement that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its MASH treatment, ...

The Notice of Allowance includes claims directed to Rezdiffra’s commercial weight-threshold dosing regimen as prescribed in the FDA-approved label. The U.S. patent scheduled to issue from this ...

The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, potentially securing long-term revenue streams for the biopharmaceutical ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. With a price target of $470, Citizens JMP analysts reiterated their ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Rezdiffra has interactions with certain drugs, such as clopidogrel, atorvastatin, and gemfibrozil. Talk with your doctor to avoid potentially harmful effects from Rezdiffra interactions.

Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain my Hold rating on MDGL stock.

About Rezdiffra Rezdiffra is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. It is the first approved medication for the treatment of MASH in ...

“Rezdiffra demonstrated broad, sustained efficacy across multiple noninvasive parameters at two years of treatment. A high, statistically significant percentage of patients with CSPH or probable ...

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis ...